<DOC>
	<DOCNO>NCT00174265</DOCNO>
	<brief_summary>This extension study A7501013 ( P05771/NCT00145496 ) test efficacy safety Asenapine compare market agent ( olanzapine ) treatment patient persistent negative symptom schizophrenia .</brief_summary>
	<brief_title>6-Month Extension Trial Asenapine With Olanzapine Negative Symptoms Patients Who Completed First 6- Month Trial ( A7501014 ) ( COMPLETED ) ( P05772 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Continue meet demographic procedural inclusion criterion A7501013 trial enter extension trial . Have demonstrate acceptable degree compliance complete A7501013 trial , would benefit continued treatment accord investigator . Have uncontrolled , unstable clinically significant medical condition . Have judge medically noncompliant management disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>